181508-22-5

Upstream product

• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 151059-70-0 N'-(9-{(2R,3R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-2-oxo-3,9-dihydro-2H-purin-6-yl)-N,N-dimethyl-formamidine 
• 156706-72-8 N'-[9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2-oxo-3,9-dihydro-2H-purin-6-yl]-N,N-dimethyl-formamidine 
• 1818-71-9 isoguanosine 
• 181508-24-7 N'-(9-{(2R,5S)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-2,5-dihydro-furan-2-yl}-2-oxo-3,9-dihydro-2H-purin-6-yl)-N,N-dimethyl-formamidine 

Relevant academic research and scientific papers

Nucleosides VIII: Synthesis of 2',3'-dideoxy- and 2',3'- didehydro- 2',3'-dideoxyisoguanosine as potential antiretroviral agents

2',3'-Didehydro-2',3'-dideoxyisoguanosine (2) and 2',3'dideoxyisoguanosine (3) have been synthesized by utilizing the Corey- Winter approach starting from isoguanosine. The 6-amino and 5'-hydroxy biprotected isoguanosine derivative was converted to the corresponding 2',3'- thionocarbonate, which was heated with triethyl phosphite to afford the 2',3'-olefinic product. Either a tert-butyldimethylsilyl or a 4,4'- dimethoxytrityl group was used in the protection of 5'-hydroxy function. Compounds 2 and 3 were found inactive against human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), and herpes simplex virus type 1 (HSV- 1).